GlassScriptPhysician profile
Michelle N Giddings
NPI 1336303072
$131,302.72
in general payments reported to CMS, 2019-2025
30 companies · $62K in 2025
The $62K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,103 · 2022: $11K · 2023: $25K · 2024: $28K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $51K · Consulting Fee: $25K · Travel and Lodging: $15K · Food and Beverage: $13K · Honoraria: $9,425 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $51,188.00 |
| Consulting Fee | $24,768.00 |
| Travel and Lodging | $15,223.04 |
| Food and Beverage | $13,464.90 |
| Honoraria | $9,425.00 |
| Education | $121.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $49,162.52 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $42,067.03 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $27,610.76 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,122.41 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,511.53 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $1,455.25 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $1,264.09 | 2021-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $1,049.85 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $1,016.29 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $864.53 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $608.71 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $402.72 | 2021-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $348.64 | 2021-2022 | |
| Corium, LLC | $289.81 | 2022-2024 | Azstarys |
| Almatica Pharma LLC | $249.37 | 2021-2024 | Loreev Xr |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $227.70 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Avanir Pharmaceuticals, INC. | $194.86 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $177.89 | 2021-2025 | Fanapt |
| Eisai INC. | $112.82 | 2021 | |
| Bioxcel Therapeutics, INC. | $112.80 | 2023 | Igalmi |
| Neuronetics, INC. | $108.76 | 2022-2024 | Neurostar Tms Therapy System |
| Bausch Health US, LLC | $80.19 | 2022-2023 | Aplenzin |
| Idorsia Pharmaceuticals US INC | $51.27 | 2023-2024 | Quviviq |
| Sage Therapeutics, LLC | $43.60 | 2024 | |
| Merck Sharp & Dohme LLC | $40.45 | 2022-2023 | Belsomra |
| Alfasigma USA, INC. | $38.69 | 2022 | |
| Tris Pharma INC | $31.89 | 2025 | Dyanavel Xr |
| Tempus Ai, INC | $25.17 | 2024 | |
| Ironshore Pharmaceuticals INC. | $18.20 | 2024 | |
| Arbor Pharmaceuticals, INC. | $14.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Giddings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.